Ritonavir（Cat No.:A000960）is an antiretroviral protease inhibitor used in the treatment of HIV infection. It inhibits the HIV-1 protease enzyme, preventing the maturation of infectious virus particles. Ritonavir is primarily used as a pharmacokinetic enhancer, or “booster,” for other protease inhibitors, increasing their effectiveness by inhibiting the cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes many drugs. By boosting the levels of co-administered antiretrovirals, Ritonavir allows for lower dosing and improved efficacy. It plays a crucial role in combination therapy, enhancing the effectiveness of HIV treatment regimens.
| Catalog Number | A000960 |
| CAS Number | 155213-67-5 |
| Synonyms | 155213-67-5; Norvir; ABT-538; A-84538; Abbott 84538 |
| Molecular Formula | C37H48N6O5S2 |
| Purity | 98% |
| Target | CYP3A4/3CL/HIV-1 |
| Target Protein | |
| Solubility | Soluble in DMSO > 10 mM |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM. |
| IUPAC Name | 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate |
| InChI | InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 |
| InChIKey | NCDNCNXCDXHOMX-XGKFQTDJSA-N |
| SMILES | CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O |
| Reference | 1: Freise KJ, Hu B, Salem AH. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol. 2018 Jan 4. doi: 10.1007/s00228-017-2403-3. [Epub ahead of print] PubMed PMID: 29302721.<br /> |
